{"id":39663,"date":"2026-11-19T11:45:29","date_gmt":"2026-11-19T16:45:29","guid":{"rendered":"https:\/\/nephcure.org\/?p=39663"},"modified":"2026-11-19T11:45:35","modified_gmt":"2026-11-19T16:45:35","slug":"the-u-s-food-and-drug-administration-approves-gazyva-obinutuzumab-as-the-first-and-only-treatment-for-primary-membranous-nephropathy","status":"publish","type":"post","link":"https:\/\/nephcure.org\/es\/the-u-s-food-and-drug-administration-approves-gazyva-obinutuzumab-as-the-first-and-only-treatment-for-primary-membranous-nephropathy\/","title":{"rendered":"The U.S. Food and Drug Administration Approves GAZYVA (obinutuzumab) as the First and Only Treatment for Primary Membranous Nephropathy"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>November 2026<\/strong> \u2014 The rare kidney disease (RKD) community celebrates a huge landmark milestone following the U.S. Food and Drug Administration\u2019s (FDA) approval of GAZYVA\u00ae (obinutuzumab) as the first and only therapy for adult patients with <a href=\"https:\/\/nephcure.org\/es\/introduccion-a-rkd\/tipos-de-rkd\/nefropatia-membranosa-mn\/\"><strong>primary membranous nephropathy (pMN)<\/strong><\/a> at risk of disease progression, to induce remission of proteinuria.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This historic approval provides patients with a targeted, disease-modifying treatment option for a serious condition with high unmet needs. Proteinuria serves as a key indicator of kidney damage and a critical predictor of long-term kidney preservation, making the achievement of complete remission a vital goal to maintain kidney function and prevent serious complications.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/nephcure.org\/es\/introduccion-a-rkd\/tipos-de-rkd\/nefropatia-membranosa-mn\/\" data-type=\"page\" data-id=\"28693\">Primary membranous nephropathy (pMN)<\/a> is a rare, chronic autoimmune condition that causes potentially irreversible kidney damage. When left untreated, up to 30% of patients progress to kidney failure within 10 years. People living with pMN often experience fatigue, edema (swelling), and significant physical and emotional challenges, placing a substantial human and economic burden on patients, families, and healthcare systems alike.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/nephcure.org\/es\/gestionando-rkd\/opciones-de-tratamiento\/gazyva-obinutuzumab-for-pmn\/\">Gazyva<\/a> is a targeted therapy designed to address B cells, a critical underlying driver of the disease. By turning decades of specialized antibody engineering into tangible outcomes, Gazyva offers a more effective approach to achieve durable disease control compared to conventional options like tacrolimus.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>The FDA approval is based on robust data from the Phase III MAJESTY study, which demonstrated:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>36.1% of adults achieving complete remission (CR) of proteinuria at two years (104 weeks) with Gazyva versus 5.7% with tacrolimus (adjusted difference 31.1%; 95% CI: 18.2 to 44.0; p&lt;0.001).<\/li>\n\n\n\n<li>Superiority in overall remission rates (complete or partial remission) at week 104 (50% vs. 12.9%; adjusted difference 37.8%; p&lt;0.001).<\/li>\n\n\n\n<li>Complete remission at week 76 (36.1% vs. 8.6%; adjusted difference 27.4%; p&lt;0.001).<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">With today\u2019s approval, there are now 13 FDA-approved treatment options for rare, protein-spilling kidney diseases, including therapies for IgAN, focal segmental glomerulosclerosis (FSGS), C3 glomerulopathy (C3G), primary IC-MPGN, and nephrotic syndrome.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/nephcure.org\/es\/gestionando-rkd\/opciones-de-tratamiento\/empaveli-pegcetacoplan\/\">EMPAVELI (pegcetacoplan)\u202f<\/a>&#8211; Approved for C3G and primary IC-MPGN&nbsp;<\/li>\n\n\n\n<li><a href=\"https:\/\/nephcure.org\/es\/gestionando-rkd\/opciones-de-tratamiento\/budesonida-tarpeyo-2\/\">FABHALTA (iptacopan)\u202f<\/a>&#8211; Approved for C3G and&nbsp;IgAN&nbsp;<\/li>\n\n\n\n<li><a href=\"https:\/\/nephcure.org\/es\/gestionando-rkd\/opciones-de-tratamiento\/filspari-sparsentan-for-igan\/\">FILSPARI (esparsent\u00e1n)<\/a>\u202f- Approved for\u202fIgAN\u202fand FSGS&nbsp;<\/li>\n\n\n\n<li><a href=\"https:\/\/nephcure.org\/es\/gestionando-rkd\/opciones-de-tratamiento\/obinutuzumab\/\">GAZYVA (obinutuzumab)<\/a> \u2013 Approved for nephrotic syndrome&nbsp;and primary membranous nephropathy<\/li>\n\n\n\n<li><a href=\"https:\/\/nephcure.org\/es\/gestionando-rkd\/opciones-de-tratamiento\/budesonida-tarpeyo\/\">TARPEYO (budesonide)\u202f<\/a>\u2013 Approved for&nbsp;IgAN&nbsp;<\/li>\n\n\n\n<li><a href=\"https:\/\/nephcure.org\/es\/gestionando-rkd\/opciones-de-tratamiento\/atacicept-trutakna\/\">TRUTAKNA (atacicept)<\/a>\u202f- Approved for&nbsp;IgAN&nbsp;<\/li>\n\n\n\n<li>ULTOMIRIS (ravulizumab) &#8211; Approved for&nbsp;IgAN&nbsp;<\/li>\n\n\n\n<li><a href=\"https:\/\/nephcure.org\/es\/gestionando-rkd\/opciones-de-tratamiento\/vanrafia-atrasentan\/\">VANRAFIA (atrasentan)<\/a>\u202f\u2013 Approved for&nbsp;IgAN&nbsp;<\/li>\n\n\n\n<li><a href=\"https:\/\/nephcure.org\/es\/gestionando-rkd\/opciones-de-tratamiento\/voyxact-sibeprenlimab\/\">VOYXACT (sibeprenlimab)<\/a>\u202f- Approved for&nbsp;IgAN&nbsp;<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>November 2026 \u2014 The rare kidney disease (RKD) community celebrates a huge landmark milestone following the U.S. Food and Drug Administration\u2019s (FDA) approval of GAZYVA\u00ae (obinutuzumab) as the first and &#8230; <a title=\"The U.S. Food and Drug Administration Approves GAZYVA (obinutuzumab) as the First and Only Treatment for Primary Membranous Nephropathy\" class=\"read-more\" href=\"https:\/\/nephcure.org\/es\/the-u-s-food-and-drug-administration-approves-gazyva-obinutuzumab-as-the-first-and-only-treatment-for-primary-membranous-nephropathy\/\" aria-label=\"Leer m\u00e1s sobre The U.S. Food and Drug Administration Approves GAZYVA (obinutuzumab) as the First and Only Treatment for Primary Membranous Nephropathy\">Leer m\u00e1s<\/a><\/p>","protected":false},"author":12083,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[300],"tags":[547,436],"disease-category":[254],"resource-type":[260],"treatment-option":[],"hf_cat_post":[537],"class_list":["post-39663","post","type-post","status-publish","format-standard","hentry","category-press-release","tag-mn","tag-treatment-options","disease-category-membranous-nephropathy-mn","resource-type-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.8 (Yoast SEO v28.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA approves GAZYVA for pMN<\/title>\n<meta name=\"description\" content=\"Learn more about GAZYVA and its impact on kidney disease treatment following FDA&#039;s accelerated approval.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nephcure.org\/es\/the-u-s-food-and-drug-administration-approves-gazyva-obinutuzumab-as-the-first-and-only-treatment-for-primary-membranous-nephropathy\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The U.S. Food and Drug Administration Approves GAZYVA (obinutuzumab) as the First and Only Treatment for Primary Membranous Nephropathy\" \/>\n<meta property=\"og:description\" content=\"Learn more about GAZYVA and its impact on kidney disease treatment following FDA&#039;s accelerated approval.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nephcure.org\/es\/the-u-s-food-and-drug-administration-approves-gazyva-obinutuzumab-as-the-first-and-only-treatment-for-primary-membranous-nephropathy\/\" \/>\n<meta property=\"og:site_name\" content=\"NephCure\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/nephcure\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-19T16:45:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-19T16:45:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/05\/Site-Image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Hillary Frawley\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@nephcure\" \/>\n<meta name=\"twitter:site\" content=\"@nephcure\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Hillary Frawley\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA approves GAZYVA for pMN","description":"Learn more about GAZYVA and its impact on kidney disease treatment following FDA's accelerated approval.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nephcure.org\/es\/the-u-s-food-and-drug-administration-approves-gazyva-obinutuzumab-as-the-first-and-only-treatment-for-primary-membranous-nephropathy\/","og_locale":"es_MX","og_type":"article","og_title":"The U.S. Food and Drug Administration Approves GAZYVA (obinutuzumab) as the First and Only Treatment for Primary Membranous Nephropathy","og_description":"Learn more about GAZYVA and its impact on kidney disease treatment following FDA's accelerated approval.","og_url":"https:\/\/nephcure.org\/es\/the-u-s-food-and-drug-administration-approves-gazyva-obinutuzumab-as-the-first-and-only-treatment-for-primary-membranous-nephropathy\/","og_site_name":"NephCure","article_publisher":"https:\/\/www.facebook.com\/nephcure\/","article_published_time":"2026-11-19T16:45:29+00:00","article_modified_time":"2026-11-19T16:45:35+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/05\/Site-Image.jpg","type":"image\/jpeg"}],"author":"Hillary Frawley","twitter_card":"summary_large_image","twitter_creator":"@nephcure","twitter_site":"@nephcure","twitter_misc":{"Escrito por":"Hillary Frawley","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nephcure.org\/the-u-s-food-and-drug-administration-approves-gazyva-obinutuzumab-as-the-first-and-only-treatment-for-primary-membranous-nephropathy\/#article","isPartOf":{"@id":"https:\/\/nephcure.org\/the-u-s-food-and-drug-administration-approves-gazyva-obinutuzumab-as-the-first-and-only-treatment-for-primary-membranous-nephropathy\/"},"author":{"name":"Hillary Frawley","@id":"https:\/\/nephcure.org\/#\/schema\/person\/7e9c2694069e66c6a918286b5a0b8272"},"headline":"The U.S. Food and Drug Administration Approves GAZYVA (obinutuzumab) as the First and Only Treatment for Primary Membranous Nephropathy","datePublished":"2026-11-19T16:45:29+00:00","dateModified":"2026-11-19T16:45:35+00:00","mainEntityOfPage":{"@id":"https:\/\/nephcure.org\/the-u-s-food-and-drug-administration-approves-gazyva-obinutuzumab-as-the-first-and-only-treatment-for-primary-membranous-nephropathy\/"},"wordCount":401,"publisher":{"@id":"https:\/\/nephcure.org\/#organization"},"keywords":["MN","Treatment Options"],"articleSection":["Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nephcure.org\/the-u-s-food-and-drug-administration-approves-gazyva-obinutuzumab-as-the-first-and-only-treatment-for-primary-membranous-nephropathy\/","url":"https:\/\/nephcure.org\/the-u-s-food-and-drug-administration-approves-gazyva-obinutuzumab-as-the-first-and-only-treatment-for-primary-membranous-nephropathy\/","name":"FDA approves GAZYVA for pMN","isPartOf":{"@id":"https:\/\/nephcure.org\/#website"},"datePublished":"2026-11-19T16:45:29+00:00","dateModified":"2026-11-19T16:45:35+00:00","description":"Learn more about GAZYVA and its impact on kidney disease treatment following FDA's accelerated approval.","breadcrumb":{"@id":"https:\/\/nephcure.org\/the-u-s-food-and-drug-administration-approves-gazyva-obinutuzumab-as-the-first-and-only-treatment-for-primary-membranous-nephropathy\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nephcure.org\/the-u-s-food-and-drug-administration-approves-gazyva-obinutuzumab-as-the-first-and-only-treatment-for-primary-membranous-nephropathy\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nephcure.org\/the-u-s-food-and-drug-administration-approves-gazyva-obinutuzumab-as-the-first-and-only-treatment-for-primary-membranous-nephropathy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nephcure.org\/"},{"@type":"ListItem","position":2,"name":"The U.S. Food and Drug Administration Approves GAZYVA (obinutuzumab) as the First and Only Treatment for Primary Membranous Nephropathy"}]},{"@type":"WebSite","@id":"https:\/\/nephcure.org\/#website","url":"https:\/\/nephcure.org\/","name":"NephCure","description":"Para enfermedades renales raras","publisher":{"@id":"https:\/\/nephcure.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nephcure.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nephcure.org\/#organization","name":"NephCure","url":"https:\/\/nephcure.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nephcure.org\/#\/schema\/logo\/image\/","url":"https:\/\/nephcure.org\/wp-content\/uploads\/2023\/03\/cropped-NephCure-favicon-512x512-1.png","contentUrl":"https:\/\/nephcure.org\/wp-content\/uploads\/2023\/03\/cropped-NephCure-favicon-512x512-1.png","width":512,"height":512,"caption":"NephCure"},"image":{"@id":"https:\/\/nephcure.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/nephcure\/","https:\/\/x.com\/nephcure","https:\/\/www.instagram.com\/nephcure\/","https:\/\/www.linkedin.com\/company\/nephcure\/","https:\/\/www.youtube.com\/user\/Nephcure"]},{"@type":"Person","@id":"https:\/\/nephcure.org\/#\/schema\/person\/7e9c2694069e66c6a918286b5a0b8272","name":"Hillary Frawley","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/244158db68c4d6cd245457294c7b816f5e5683dbceecd4244d333e8bdee042c3?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/244158db68c4d6cd245457294c7b816f5e5683dbceecd4244d333e8bdee042c3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/244158db68c4d6cd245457294c7b816f5e5683dbceecd4244d333e8bdee042c3?s=96&d=mm&r=g","caption":"Hillary Frawley"}}]}},"_links":{"self":[{"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/posts\/39663","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/users\/12083"}],"replies":[{"embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/comments?post=39663"}],"version-history":[{"count":1,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/posts\/39663\/revisions"}],"predecessor-version":[{"id":39664,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/posts\/39663\/revisions\/39664"}],"wp:attachment":[{"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/media?parent=39663"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/categories?post=39663"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/tags?post=39663"},{"taxonomy":"disease-category","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/disease-category?post=39663"},{"taxonomy":"resource-type","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/resource-type?post=39663"},{"taxonomy":"treatment-option","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/treatment-option?post=39663"},{"taxonomy":"hf_cat_post","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/hf_cat_post?post=39663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}